On March 18, 2022, the U.S. Food and Drug Administration (FDA) approved nivolumab and relatlimab-rmbw for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Read the FDA announcement.

Read Bristol Myers Squibb's announcement.

Posted 3/21/2022